NYSEMKT: CHROChromocell Therapeutics Corp Stock
$1.75-0.26 (-12.94%)
Updated May 17, 2024
CHRO Price
$1.75
Fair Value Price
N/A
Market Cap
$10.09M
52 Week Low
$1.21
52 Week High
$6.00
P/E
-0.25x
P/B
8.93x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$8.98M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
2.57
Operating Cash Flow
-$3M
Beta
-0.26
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
Zen Score
–
Industry Average (22)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CHRO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CHRO is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CHRO is poor value based on its book value relative to its share price (8.93x), compared to the US Biotechnology industry average (6.01x)
P/B vs Industry Valuation
CHRO is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more CHRO due diligence checks available for Premium users.
Be the first to know about important CHRO news, forecast changes, insider trades & much more!
CHRO News
Valuation
CHRO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.25x
Industry
8.47x
Market
30.97x
CHRO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
8.93x
Industry
6.01x
CHRO is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CHRO's financial health
Profit margin
Revenue
$0.0
Net Income
-$2.6M
Profit Margin
0%
CHRO's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$4.0M
Liabilities
$2.9M
Debt to equity
2.57
CHRO's short-term assets ($4.03M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CHRO's short-term assets ($4.03M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CHRO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.0M
Investing
$0.0
Financing
$5.7M
CHRO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CHRO vs Biotech Stocks
Chromocell Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.